A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats

Molecular Pharmacology

Volumn 54, Issue 5, 1998, Pages 864-873

  Baumbach, William R ^a   Carrick, Tikva A ^a   Pausch, Mark H ^a   Bingham, Brendan ^a   Carmignac, Danielle ^b   Robinson, Iain C A F ^b   Houghten, Richard ^c   Eppler, C Mark ^a   Price, Laura A ^a   Zysk, John R ^a,d  

^a PFIZER INC   (United States)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^d Caliper Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 178335; CELL SURFACE RECEPTOR; GROWTH HORMONE; HEXAPEPTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0031755689     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.5.864     Document Type: Article

References (40)

1. Aguila MC, Boggaram V, and McCann SM (1993) Insulin-like growth factor I modulates hypothalamic somatostatin through a growth hormone releasing factor increased somatostatin release and messenger ribonucleic acid levels. Brain Res 625:213-218.
2. Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, and Hadcock JR (1996) Identification and characterization of novel somatostatin antagonists. Mol Pharmacol 50:709-715.
3. Baumbach WR, Carrick TA, Carmignac DF, Robinson ICAF, Pausch MH, Bingham B, Houghten RA, and Zysk JR (1997) A linear hexapeptide somatostatin (SRIF) antagonist blocks SRIF activity in vitro and induces growth hormone release in rats. Proceedings of the 79th Annual Meeting of the Endocrine Society, p. 128, Endocrine Society Press, Bethesda, MD.
4. Beaudet A, Greenspun D, Railson J, and Tannenbaum GS (1995) Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function. Neuroscience 65:551-561.
5. Blondelle SE, Takahashi E, Dinh KT, and Houghten RA (1995) The antimicrobial activity of hexapeptides derived from synthetic combinatorial libraries. J Appl Bacteriol 78:39-46.
6. 2-adrenoceptor. Nature (Lond) 374:272-276.
7. Bowers CY, Momany FA, Reynolds GA, and Hong A (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545.
8. Cai R-Z, Szoke B, Lu R, Fu D, Redding TW, and Schally AV (1986) Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 83:1896-1900.
9. Carrick TA, Bingham B, Eppler CM, Baumbach WR, and Zysk JR (1995) A rapid and sensitive binding assay for growth hormone releasing factor. Endocrinology 136: 4701-4704.
10. Cheng K, Chan WW, Butler B, Wei L, Schoen WR, Wyvratt MJ Jr, Fisher MH, and Smith RG (1993) Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology 132:2729-2731.
11. Clark RG, Carlsson LMS, Rafferty B, and Robinson ICAF (1988) The rebound release of growth hormone (GH) following somatostatin infusion in rats involves hypothalamic GH-releasing factor release. J Endocrinol 119:397-404.
12. Clark RG, Carlsson LMS, Trojnar J, and Robinson ICAF (1989) The effects of a growth hormone releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1:249-255.
13. Clark RG and Robinson ICAF (1988) Paradoxical growth-promoting effects induced by patterned infusions of somatostatin in female rats. Endocrinology 122:2675-2682.
14. Dooley CT, Chung NN, Wilkes BC, Schiller PW, Bidlack JM, Pasternak GW, and Houghten RA (1994) An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science (Washington DC) 266:2019-2022.
15. Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE, Somers TC, Stanley MS, and Cronin MJ (1995) In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 136:5694-5699.
16. Eppler CM, Zysk JR, Corbett M, and Shieh H-M (1992) Purification of a pituitary receptor for somatostatin. J Biol Chem 267:15603-15612.
17. Gillies G (1997) Somatostatin: the neuroendocrine story. Trends Pharmacol Sci 18:87-95.
18. Guichard G, Benkirane N, Zeder-Lutz G, Van Regenmortel MHV, Briand J-P, and Muller S (1994) Antigenic mimicry of natural L-peptides with retro-inversopeptidomimetics. Proc Natl Acad Sci USA 91:9765-9769.
19. Hipkin RW, Friedman J, Clark RB, Eppler CM, and Schonbrunn A (1997) Agonistinduced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272:13869-13876.
20. Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT, and Cuervo JH (1991) Generation and use of synthetic peptide libraries for basic research and drug discovery. Nature (Lond) 354:84-86.
21. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong S-S, Chaung L-Y, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, and Van der Ploeg LHT (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (Washington DC) 273:974-977.
22. Koch BD and Schonbrunn A (1984) The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. Endocrinology 114:1784-1790.
23. Lambert S, Krenning E, and Reubi J (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482.
24. McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, Wada HG, and Pitchford S (1992) The Cytosensor microphysiometer: biological applications of silicon technology. Science (Washington DC) 257:1906-1912.
25. Murphy WA, Heiman ML, Lance VA, Mezo I, and Coy DH (1985) Octapeptide analogs of somatostatin exhibiting greatly enhanced in vivo and in vitro inhibition of growth hormone secretion in the rat. Biochem Biophys Res Commun 132:922-928.
26. Murphy WA, Rossowski WJ, and Coy DH (1997) Octapeptide somatostatin analogs with in vitro and in vivo antagonist activity in the rat. Proceedings of the 79th Annual Meeting of the Endocrine Society. p. 147, The Endocrine Society Press, Bethesda, MD.
27. Painson J-C and Tannenbaum GS (1991) Sexual dimorphism of somatostatin and growth hormone-releasing factor signaling in the control of pulsatile growth hormone secretion in the rat. Endocrinology 128:2858-2866.
28. Price LA, Kajkowski EM, Hadcock JR, Ozenberger BA, and Pausch MH (1995) Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway. Mol Cell Biol 15:6188-6195.
29. Raynor K, Murphy WA, Coy DH, Taylor JE, Morear JP, Yasuda K, Bell GI, and Reisine T (1993) Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 43:838-844.
30. Reisine T and Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16:427-442.
31. Strnad J, Eppler CM, Corbett M, and Hadcock JR (1993) The rat SSTR2 somatostatin receptor subtype is coupled to inhibition of cyclic AMP accumulation. Biochem Biophys Res Commun 191:968-976.
32. Tannenbaum GS (1988) Somatostatin as a physiological regulator of pulsatile growth hormone secretion. Horm Res 29:70-74.
33. Tannenbaum GS, McCarthy GF, Zeitler P, and Beaudet A (1990) Cysteamine-isteaminenduced enhancement of growth hormone-releasing factor (GRF) immunoreactivity in arcuate neurons: morphological evidence for putative somatostatin/GRF interactions within hypothalamus. Endocrinology 127:2551-2560.
34. Tannenbaum GS, Painson J-C, Lengyel AM, and Brazeau P (1989) Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH-releasing factor in the face of high somatostatin tone. Endocrinology 124:1380-1388.
35. Tentier JJ, Hadcock JR, and Gutierrez-Hartmann A (1997) Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol Endocrinol 11:859-866.
36. Thomas CR, Groot K, and Arimura A (1985) Antiserum to rat growth hormone (GH)-releasing factor suppresses but does not abolish anti-somatostatin-induced GH release in the rat. Endocrinology 116:2174-2178.
37. Turner JP and Tannenbaum GS (1995) In vivo evidence of a positive role for somatostatin to optimize pulsatile growth hormone secretion. Am J Physiol 269: E683-E690.
38. Veber DF, Freidinger RM, Perlow DS, Paleveda WJ Jr, Holly FW, Strachan RG, Nutt RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, and Hirschmann R (1981) A potent cyclic hexapeptide analogue of somatostatin. Nature (Lond) 292:55-58.
39. 5 receptor. Br J Pharm 118:445-447.
40. Yamashita S and Melmed S (1986) Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118:176-182.